KRAS and colorectal carcinoma: Still, since approximately 10 and 34% of CRC cases harbor the BRAF and KRAS hotspot variants, respectively [42], a large proportion of CRC patients will benefit from this highly sensitive and cost-effective ctDNA analysis method.